Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
2.900
-0.010 (-0.34%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Anixa Biosciences Balance Sheet
Financials in millions USD. Fiscal year is November - October.
Millions USD. Fiscal year is Nov - Oct.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Cash & Equivalents | 1.4 | 1.24 | 1.27 | 0.92 | 12.36 | 29.13 |
Short-Term Investments | 12.47 | 13.93 | 18.65 | 22.93 | 17.33 | 6.6 |
Cash & Short-Term Investments | 13.86 | 15.17 | 19.92 | 23.84 | 29.69 | 35.73 |
Cash Growth | -13.51% | -23.84% | -16.44% | -19.68% | -16.91% | 294.47% |
Other Receivables | - | - | 0.17 | 0.27 | 0.05 | - |
Receivables | - | - | 0.17 | 0.27 | 0.05 | - |
Prepaid Expenses | 1.05 | 0.71 | 1.27 | 1.24 | 0.47 | 0.28 |
Total Current Assets | 14.91 | 15.89 | 21.36 | 25.36 | 30.2 | 36 |
Property, Plant & Equipment | 0.16 | 0.19 | 0.23 | 0.17 | 0.21 | 0.25 |
Total Assets | 15.07 | 16.08 | 21.59 | 25.52 | 30.41 | 36.26 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Accounts Payable | 0.28 | 0.17 | 0.53 | 0.21 | 0.27 | 0.14 |
Accrued Expenses | 1.42 | 1.76 | 1.95 | 1.77 | 1.73 | 1.1 |
Current Portion of Leases | 0.05 | 0.04 | 0.03 | 0.05 | 0.05 | 0.04 |
Total Current Liabilities | 1.75 | 1.97 | 2.5 | 2.03 | 2.04 | 1.27 |
Long-Term Leases | 0.13 | 0.16 | 0.2 | 0.12 | 0.18 | 0.22 |
Total Liabilities | 1.87 | 2.13 | 2.7 | 2.15 | 2.21 | 1.49 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Common Stock | 0.35 | 0.33 | 0.32 | 0.31 | 0.31 | 0.3 |
Additional Paid-In Capital | 273.49 | 266.51 | 260.43 | 252.22 | 247.12 | 239.93 |
Retained Earnings | -259.36 | -251.68 | -240.75 | -228.2 | -218.39 | -204.79 |
Treasury Stock | - | - | -0.01 | - | - | - |
Total Common Equity | 14.47 | 15.16 | 20 | 24.34 | 29.05 | 35.44 |
Minority Interest | -1.27 | -1.21 | -1.11 | -0.97 | -0.85 | -0.67 |
Shareholders' Equity | 13.2 | 13.95 | 18.89 | 23.37 | 28.2 | 34.77 |
Total Liabilities & Equity | 15.07 | 16.08 | 21.59 | 25.52 | 30.41 | 36.26 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Total Debt | 0.17 | 0.2 | 0.23 | 0.18 | 0.22 | 0.26 |
Net Cash (Debt) | 13.69 | 14.97 | 19.69 | 23.67 | 29.47 | 35.47 |
Net Cash Growth | -13.44% | -23.98% | -16.80% | -19.67% | -16.92% | 294.01% |
Net Cash Per Share | 0.41 | 0.46 | 0.62 | 0.76 | 0.97 | 1.24 |
Filing Date Shares Outstanding | 34.76 | 33.38 | 32.19 | 31.7 | 30.92 | 30.13 |
Total Common Shares Outstanding | 34.58 | 33.01 | 32.19 | 31.15 | 30.91 | 30.05 |
Working Capital | 13.17 | 13.92 | 18.86 | 23.33 | 28.16 | 34.73 |
Book Value Per Share | 0.42 | 0.46 | 0.62 | 0.78 | 0.94 | 1.18 |
Tangible Book Value | 14.47 | 15.16 | 20 | 24.34 | 29.05 | 35.44 |
Tangible Book Value Per Share | 0.42 | 0.46 | 0.62 | 0.78 | 0.94 | 1.18 |